Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1643
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18274307 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | Non-Final OA | The Regents of the University of California |
| 17291376 | Methods Employing Mucin-Specific Proteases | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17798983 | ANTI-BCMA THERAPY IN AUTOIMMUNE DISORDERS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17602949 | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17741166 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 | Final Rejection | The General Hospital Corporation |
| 17177396 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18246585 | COMBINATION OF P2Y6 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | Non-Final OA | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D |
| 17058896 | LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18280379 | ANTI-CLDN6 ANTIBODY AND USE THEREOF | Non-Final OA | SHANGHAI GENBASE BIOTECHNOLOGY CO., LTD. |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Final Rejection | Inhibrx Biosciences, Inc. |
| 18276582 | CCR4-Targeting Chimeric Antigen Receptor Cell Therapy | Non-Final OA | NATIONIAL CANCER CENTER |
| 18009713 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18269240 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES | Non-Final OA | SOTIO Biotech a.s. |
| 17998032 | SOLUBLE TCRS AND FUSIONS TO ANTI-CD3 RECOGNIZING KRAS G12D FOR THE TREATMENT OF CANCER | Non-Final OA | IMMUNOCORE LIMITED |
| 17255546 | CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN | Non-Final OA | Albert-Ludwigs-Universitaet Freiburg |
| 17320200 | IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS | Non-Final OA | ACTYM THERAPEUTICS, INC. |
| 16870715 | VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF | Final Rejection | Merus B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy